T Cell News and Research

Latest T Cell News and Research

Immune responses with and without previous SARS-CoV-2 infection following single BNT162b2 vaccine dose

The Protective Immunity from T-cells to COVID-19 in Healthcare workers (PITCH) is a prospective, cohort, multi-center study enclosed within the SIREN study designed to assess the effectiveness of the BNT162b2 vaccine in healthcare workers.

12 Nov 2021

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

A paper published in the open-access journal Viruses, reports on a study investigating long-term changes to soluble inflammatory factors and cellular immune phenotype and function in 22 survivors of mild SARS-CoV-2 infection. The observations were then compared to 11 individuals who had recovered from other mild respiratory infections.

10 Nov 2021

The SARS-CoV-2 Beta variant evades Fc effector function by ancestral strain, study says

A new study finds improved Fc cross-reactivity against certain SARS-CoV-2 variant of concern.

10 Nov 2021

Elusive white blood cells play a role in impaired T cell functions and counts in people with HIV

In a groundbreaking study of people living with HIV, University of Alberta researchers found that elusive white blood cells called neutrophils play a role in impaired T cell functions and counts, as well as the associated chronic inflammation that is common with the virus.

9 Nov 2021

A measles-vectored COVID-19 vaccine induces strong immunity in animal model

A new study explores the potential of MV-based vaccines targeting the S protein of SARS-CoV-2.

9 Nov 2021

The role of T follicular helper cells in the humoral immune response to SARS-CoV-2

The current analysis indicates that cTfh cells react to the spike antigen following vaccination are associated with anti-S protein neutralizing antibodies.

9 Nov 2021

Enhanced neutralizing antibody and T-cell responses by DNA-based vaccine encoding SARS-CoV-2 spike protein

Researchers from VaxiGen have been investigating the potential for a DNA vaccine boost to VP vaccines against coronavirus disease 2019.

9 Nov 2021

Pfizer COVID-19 vaccine elicits durable specific memory T-cell response

A new preprint describes the protective efficacy of memory T-cells developed in response to the viral antigen, which could offer long-term immunity.

4 Nov 2021

Novel model-based framework evaluates immune mechanism of COVID-19 vaccine response

A model framework for characterizing viral dynamics and vaccine efficacy in non-human primates is described and applied to the identification of correlates of protection in three independent vaccine studies.

4 Nov 2021

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

A comprehensive characterization of the immune responses between SARS-CoV-2 infected individuals with wildtype (WT) and Δ382 SARS-CoV-2.

3 Nov 2021

Cross-reactive immunity against coronaviruses

Researchers review the heterologous immunity to coronaviruses and the extent of immune cross-reactivity against SARS-CoV-2.

3 Nov 2021

Pre-clinical follow-up study boosting with original formulation and next generation INO-4802 SARS-CoV-2 vaccine candidate

Researchers describe the antibody-inducing effects of DNA-based synthetic vaccines INO-4800 and INO-4802 against SARS-CoV-2 in non-human primates.

3 Nov 2021

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

2 Nov 2021

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.

2 Nov 2021

IBD patients produce a strong antibody response to COVID-19 vaccination, finds study

Researchers at Cedars-Sinai found that patients with inflammatory bowel disease (IBD)─whose treatment can weaken the immune system─produced a strong antibody response to COVID-19 vaccination.

2 Nov 2021

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination.

2 Nov 2021

Understanding the current medical landscape of prostate cancer

In this interview, News-Medical talks to Dr. Simon Chowdhury and Laetitia Guilloux about the current state of prostate cancer, it's prevalence, treatment options and its future.

From Janssen Pharmaceuticals 2 Nov 2021

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Researchers look to gain an understanding of the mechanism of action of budesonide in improving the prognosis of patients with SARS-CoV-2 infection.

1 Nov 2021

Two new studies show how to enhance effectiveness of cancer immunotherapy

Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and tumors of patients that would show how likely it is that someone would respond to immunotherapy.

30 Oct 2021

How long does natural or vaccine-induced immunity to COVID last?

Researchers present a comprehensive assessment on SARS-CoV-2 induced immunity.

28 Oct 2021

Previous
1
...
46
47
48
49
50
51
52
...
2905
Next

T Cell News and Research

Latest T Cell News and Research

Immune responses with and without previous SARS-CoV-2 infection following single BNT162b2 vaccine dose

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

The SARS-CoV-2 Beta variant evades Fc effector function by ancestral strain, study says

Elusive white blood cells play a role in impaired T cell functions and counts in people with HIV

A measles-vectored COVID-19 vaccine induces strong immunity in animal model

The role of T follicular helper cells in the humoral immune response to SARS-CoV-2

Enhanced neutralizing antibody and T-cell responses by DNA-based vaccine encoding SARS-CoV-2 spike protein

Pfizer COVID-19 vaccine elicits durable specific memory T-cell response

Novel model-based framework evaluates immune mechanism of COVID-19 vaccine response

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

Cross-reactive immunity against coronaviruses

Pre-clinical follow-up study boosting with original formulation and next generation INO-4802 SARS-CoV-2 vaccine candidate

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

IBD patients produce a strong antibody response to COVID-19 vaccination, finds study

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

Understanding the current medical landscape of prostate cancer

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Two new studies show how to enhance effectiveness of cancer immunotherapy

How long does natural or vaccine-induced immunity to COVID last?

Immunology eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in